Neoadjuvant Chemotherapy in India

Neoadjuvant chemotherapy in India is chemotherapy given before the main cancer treatment, usually surgery. It is used for selected cancers when shrinking the tumour, treating microscopic cancer cells early, improving the chances of complete surgery, or assessing how the cancer responds to treatment may be beneficial.

Neoadjuvant chemotherapy is not a single treatment protocol. The medicines, number of cycles, treatment duration, need for radiation or immunotherapy, and timing of surgery depend on the cancer type, stage, tumour biology, imaging findings, overall health, and treatment goals.

There is a named GAF Healthcare partner planning sheet for neoadjuvant chemotherapy: $2,500–$10,000, typically Cycles before surgery · 2–4 months. Neighbouring United States comparison figures on the same sheet are $15,000–$45,000. That India band is a pathway planning range for oncology review, pre-operative cycles and associated day-care. It is not the price of a single infusion and it is not a whole-cancer package.

Neighbouring adjuvant chemotherapy is $2,500–$10,000, typically cycles after surgery · 3–6 months. Neighbouring chemotherapy is $1,500–$8,000+, typically outpatient cycles over 3–6 months. Named chemotherapy lists sit on Chemotherapy in India. Neighbouring palliative chemotherapy is $1,500–$7,000. Neighbouring immunotherapy is $15,000–$45,000. Neighbouring targeted therapy is $8,000–$30,000. Neighbouring molecular targeted therapy is $10,000–$32,000. Neighbouring hormone therapy is $1,000–$4,500. Neighbouring precision oncology is $2,000–$7,000. Neighbouring maintenance therapy is $4,000–$18,000. Neighbouring intraperitoneal chemotherapy is $5,000–$14,000.

Disease pathways sit on breast cancer treatment in India, colon cancer treatment in India, ovarian cancer treatment in India, pancreatic cancer treatment in India, Whipple surgery in India, bile duct cancer surgery in India and cervical cancer treatment in India. Post-operative lists sit on adjuvant chemotherapy in India. Radiation lists sit on external beam radiotherapy in India, brachytherapy in India and proton beam therapy in India. There is no live GAF lung-cancer-only, gastric-cancer-only, oesophageal-cancer-only, bladder-cancer-only, osteosarcoma-only or rectal-cancer-only treatment page.

Important: Neoadjuvant chemotherapy is appropriate only for selected patients. The treating oncology team should determine whether chemotherapy before surgery is suitable after reviewing pathology, imaging, staging and other relevant medical information. A quotation should be obtained only after records review.

What is neoadjuvant chemotherapy?

Neoadjuvant chemotherapy is systemic cancer treatment administered before the definitive local treatment, most commonly surgery.

The term “neoadjuvant” describes the timing of treatment, not a particular chemotherapy drug. Neoadjuvant treatment can include chemotherapy alone or, depending on the cancer, chemotherapy combined with radiation therapy, immunotherapy or other systemic treatments.

The main idea is straightforward: instead of removing the tumour immediately, the oncology team may first treat the cancer systemically and then reassess it before surgery.

This approach can be particularly useful when the tumour is large, locally advanced, involves nearby lymph nodes, or when reducing tumour burden could make surgery more feasible.

Why is chemotherapy given before surgery?

There are several reasons an oncologist may recommend chemotherapy before surgery.

1. To shrink the primary tumour

Chemotherapy can reduce tumour size in cancers that are sensitive to systemic treatment.

A smaller tumour may make surgery technically easier or, in selected situations, allow an organ-preserving operation that might otherwise be difficult.

For example, neoadjuvant chemotherapy may be used in selected breast cancers to shrink a tumour sufficiently to make breast-conserving surgery possible. See breast cancer treatment in India.

2. To treat microscopic cancer cells early

Cancer can sometimes spread microscopically even when scans show no distant metastases.

Systemic chemotherapy reaches cancer cells throughout the body rather than only treating the visible primary tumour.

This is one reason preoperative systemic treatment can be considered in cancers with a meaningful risk of distant recurrence.

3. To make an initially difficult tumour more operable

Some cancers are considered borderline resectable or locally advanced at diagnosis.

Treatment before surgery may reduce tumour involvement or improve the possibility of obtaining a complete surgical resection.

Pancreatic cancer is an important example in which neoadjuvant treatment is incorporated into treatment strategies for selected resectable or borderline-resectable disease. See pancreatic cancer treatment in India and Whipple surgery in India.

4. To observe how the cancer responds

The tumour’s response to preoperative treatment provides useful information to the multidisciplinary team.

A strong response can provide evidence that the cancer is sensitive to the selected treatment.

Conversely, progression during neoadjuvant treatment may lead the team to reconsider the treatment strategy before proceeding with a major operation.

5. To potentially improve the chances of complete surgery

For some cancers, reducing the tumour before surgery can help surgeons achieve a complete resection with appropriate margins.

However, this benefit is cancer-specific and should not be assumed for every tumour.

Neoadjuvant versus adjuvant chemotherapy

One of the most common questions is the difference between chemotherapy before and after surgery.

Feature	Neoadjuvant chemotherapy	Adjuvant chemotherapy
Timing	Before surgery	After surgery
Main purpose	Treat tumour before definitive local treatment	Treat possible residual microscopic disease after surgery
Tumour size	May shrink the primary tumour	Primary tumour has already been removed
Response assessment	Can be assessed before surgery	Pathology after surgery helps assess disease characteristics
Surgical implications	May facilitate surgery in selected cancers	Surgery has already taken place
GAF Healthcare India planning	$2,500–$10,000	$2,500–$10,000
Typical stay on the cost sheet	Cycles before surgery · 2–4 months	Cycles after surgery · 3–6 months

Some patients receive both neoadjuvant and postoperative systemic treatment as part of a perioperative treatment plan.

For example, gastric and oesophageal cancers may be treated using perioperative approaches in which systemic therapy is given around the time of surgery. There is no live GAF gastric-cancer-only or oesophageal-cancer-only treatment page.

Named post-operative lists sit on adjuvant chemotherapy in India. Neighbouring adjuvant chemotherapy is a different sheet and is not a neoadjuvant quotation.

Which cancers can be treated with neoadjuvant chemotherapy?

Neoadjuvant chemotherapy is used in several cancer types, but its role differs considerably between diseases.

Breast cancer

Neoadjuvant systemic therapy is commonly considered for selected patients with locally advanced or biologically aggressive breast cancer.

The NCI identifies several situations where chemotherapy before surgery may be recommended, including some patients with large tumours, lymph-node involvement, high-grade disease, HER2-positive breast cancer, triple-negative breast cancer and inflammatory breast cancer.

Treatment may include chemotherapy combined with targeted therapy or immunotherapy when indicated by tumour biology. Named molecular-matched lists sit on Molecular Targeted Therapy in India.

One important advantage is that the response can be assessed before surgery. The pathology obtained at surgery can also provide information about how much viable cancer remains after preoperative treatment.

See breast cancer treatment in India and chemotherapy for breast cancer.

Rectal cancer

Rectal cancer is an area where the concept of neoadjuvant treatment has evolved substantially.

For selected stage II and III rectal cancers, preoperative treatment can include chemoradiation, chemotherapy, short-course radiation followed by chemotherapy, or total neoadjuvant therapy (TNT).

NCI guidance describes TNT as an approach in which chemotherapy and radiation are delivered before surgery, with the sequence determined by the treatment plan.

For selected lower-risk patients, neoadjuvant FOLFOX without routine preoperative chemoradiation has also been studied. The PROSPECT trial evaluated this approach in patients with selected clinically staged rectal cancers who were candidates for sphincter-sparing surgery.

There is no live GAF rectal-cancer-only treatment page. The named surgical sheet is rectal cancer surgery. Neighbouring colon lists sit on colon cancer treatment in India and colon cancer chemotherapy. Radiation lists sit on external beam radiotherapy in India.

Oesophageal cancer

Locally advanced oesophageal and gastroesophageal junction cancers may require multimodal treatment.

Depending on tumour location, histology, stage and institutional protocol, treatment before surgery may include chemotherapy or chemoradiotherapy.

The CROSS trial established important evidence for preoperative chemoradiotherapy using carboplatin and paclitaxel in operable oesophageal or gastroesophageal junction cancer.

The precise approach should be determined by a multidisciplinary oesophageal cancer team. There is no live GAF oesophageal-cancer-only treatment page.

Gastric cancer

For selected locally advanced gastric cancers, chemotherapy may be administered before and after surgery as part of a perioperative treatment strategy.

The rationale is to treat systemic disease early while also treating the primary tumour before surgery.

NCI guidance notes that treatment before surgery can be used to shrink gastric tumours and reduce the amount of tissue that may need to be removed.

Treatment decisions depend on stage, tumour location, histology, resectability and the patient’s overall condition. There is no live GAF gastric-cancer-only treatment page.

Pancreatic cancer

Pancreatic cancer requires particularly careful assessment of resectability.

Patients may be classified as resectable, borderline resectable, locally advanced or metastatic based on imaging and other clinical factors.

Neoadjuvant therapy, including chemotherapy with or without chemoradiation, is an established treatment consideration for borderline-resectable pancreatic cancer and is being studied in other potentially operable settings.

Regimens can include multi-drug combinations such as modified FOLFIRINOX in appropriately selected patients.

Because pancreatic surgery is complex, treatment should ideally be coordinated through a multidisciplinary high-volume pancreatic cancer team. See pancreatic cancer treatment in India and Whipple surgery in India.

Non-small cell lung cancer

Neoadjuvant treatment has become increasingly important in selected resectable non-small cell lung cancers.

Depending on stage and molecular characteristics, patients may receive chemotherapy alone or chemotherapy combined with immunotherapy.

NCI guidance now includes neoadjuvant chemotherapy and neoadjuvant chemo-immunotherapy among treatment options for selected resectable stage II and IIIA NSCLC.

The CheckMate 816 trial showed improved event-free survival and pathological complete response with nivolumab plus platinum-based chemotherapy compared with chemotherapy alone in appropriately selected resectable NSCLC.

This illustrates why modern neoadjuvant treatment is increasingly based on both stage and tumour biology. There is no live GAF lung-cancer-only treatment page. Neighbouring immunotherapy is $15,000–$45,000.

Bladder cancer

Neoadjuvant cisplatin-based combination chemotherapy is an important component of treatment for selected patients with muscle-invasive bladder cancer who are candidates for radical cystectomy and are medically suitable for cisplatin.

The rationale includes treating occult systemic disease early and potentially downstaging the tumour before bladder removal.

NCI reports that randomised evidence supports cisplatin-based combination chemotherapy before cystectomy, including an absolute improvement in five-year overall survival in meta-analysis.

Not every patient can safely receive cisplatin, so kidney function, hearing, performance status and other factors must be assessed. There is no live GAF bladder-cancer-only treatment page.

Osteosarcoma

Osteosarcoma is a classic example where chemotherapy is frequently integrated before and after surgery.

Preoperative chemotherapy can shrink the tumour and may help facilitate limb-sparing surgery.

NCI states that chemotherapy is usually administered before and after surgery for localised osteosarcoma, with treatment involving combinations of agents such as high-dose methotrexate, doxorubicin and cisplatin in established protocols.

The treatment plan should be managed by an experienced sarcoma team. There is no live GAF osteosarcoma-only or sarcoma-only treatment page.

Cervical cancer

The role of neoadjuvant chemotherapy in cervical cancer is more nuanced.

Chemotherapy before surgery has been studied as a way of potentially converting selected patients into candidates for radical surgery.

However, concurrent chemoradiation remains an established treatment approach for many patients with locally advanced cervical cancer, and NCI describes neoadjuvant chemotherapy in cervical cancer as an area with ongoing clinical evaluation rather than a universal standard for all patients.

Therefore, cervical cancer treatment should be individualised according to stage, tumour characteristics, surgical options and multidisciplinary assessment. See cervical cancer treatment in India, external beam radiotherapy in India and brachytherapy in India.

Ovarian cancer

In selected advanced ovarian cancers, chemotherapy may be given first, followed by interval cytoreductive surgery and further chemotherapy.

See ovarian cancer treatment in India. Neighbouring intraperitoneal chemotherapy in India is a different regional route.

Who may be a candidate?

A patient may be considered for neoadjuvant chemotherapy when several clinical factors support treatment before surgery.

These may include a large primary tumour, locally advanced cancer, regional lymph-node involvement, borderline-resectable disease, a tumour that may become easier to remove after systemic treatment, a cancer known to respond to systemic chemotherapy, a high risk of microscopic systemic disease, a treatment strategy in which tumour response provides useful information, a need to preserve an organ or improve the possibility of less extensive surgery, or a cancer-specific guideline recommending or supporting preoperative systemic treatment.

However, tumour size alone does not determine whether neoadjuvant chemotherapy is appropriate.

The decision is usually made after staging and multidisciplinary discussion.

When may neoadjuvant chemotherapy not be appropriate?

Neoadjuvant chemotherapy may not be appropriate when the cancer is better treated with immediate surgery, the tumour is not sufficiently sensitive to the proposed chemotherapy, the patient cannot safely tolerate the regimen, significant organ dysfunction limits treatment options, there is uncontrolled infection or another major medical problem, the cancer has progressed to a stage where surgery is no longer the planned definitive treatment, urgent surgery is required, or another treatment approach is more appropriate based on tumour biology.

For some cancers, neoadjuvant therapy remains under investigation or is appropriate only for carefully selected patients.

Tests before neoadjuvant chemotherapy

Before treatment starts, the oncology team usually needs enough information to establish the diagnosis, stage the cancer and assess whether the patient can safely receive the proposed regimen.

Biopsy and pathology

A tissue biopsy usually establishes the cancer diagnosis. Pathology may also identify tumour characteristics that affect treatment selection.

Imaging

Depending on the cancer, imaging can include CT, MRI, PET-CT, ultrasound, mammography, endoscopic ultrasound and other disease-specific studies.

Blood tests

Common assessments include complete blood count, kidney function, liver function, electrolytes and other cancer-specific laboratory tests.

Cardiac assessment

Some chemotherapy drugs can affect the heart. Patients receiving potentially cardiotoxic treatment may require an ECG or echocardiogram before treatment.

Biomarker testing

Modern cancer treatment increasingly relies on molecular and biomarker information. Depending on the cancer, testing may include HER2, hormone receptors, PD-L1, MSI/MMR, EGFR, ALK and other actionable genomic alterations. Named endocrine-therapy lists sit on Hormone Therapy in India.

The exact tests depend on the cancer type and treatment plan. Neighbouring precision oncology is $2,000–$7,000. Named genomic-testing lists sit on Precision Oncology in India.

How neoadjuvant chemotherapy is given

The chemotherapy may be administered through an intravenous infusion, a central venous catheter, a PICC line, an implanted port, oral chemotherapy medicines, or a combination of intravenous and oral treatment.

Many chemotherapy regimens can be delivered through a day-care oncology unit, allowing the patient to return home after treatment.

Some regimens require longer observation or hospital admission.

The schedule depends entirely on the drugs being used.

How many cycles are needed?

There is no universal number of cycles.

Depending on the cancer, treatment may involve several cycles over several weeks or months.

Some modern treatment programmes are structured around a fixed number of preoperative cycles, while others are adapted according to response and toxicity.

For example, NCI describes three cycles of platinum-based chemotherapy in some historical neoadjuvant NSCLC trials, while contemporary chemo-immunotherapy protocols can use different schedules.

In pancreatic cancer, published neoadjuvant protocols can involve multiple cycles before surgery.

The number of cycles should therefore never be estimated solely from the phrase “neoadjuvant chemotherapy.”

How long does neoadjuvant chemotherapy take?

The duration depends on cancer type, chemotherapy regimen, number of cycles, treatment interval, response to treatment, side effects, need for radiation, need for immunotherapy or targeted therapy, and timing and availability of surgery.

A treatment plan may take several weeks to several months before surgery. GAF Healthcare partner planning is $2,500–$10,000, typically Cycles before surgery · 2–4 months.

The surgery date is generally determined after the oncology team completes the planned preoperative treatment and restaging.

What happens after neoadjuvant chemotherapy?

After the planned treatment, the patient is reassessed.

This may involve physical examination, blood tests, CT, MRI, PET-CT, endoscopy, ultrasound and disease-specific tumour markers.

The purpose is to determine whether the tumour has responded, remained stable, progressed, or become more or less suitable for surgery.

The multidisciplinary team then decides whether to proceed with surgery, modify the treatment plan, administer additional treatment, or consider another strategy.

What is a pathological complete response?

A pathological complete response (pCR) generally means that no residual viable cancer is identified in the tissue examined after neoadjuvant treatment and surgery, according to the definition used for that cancer and clinical study.

pCR can be an important measure of response in several cancers, particularly breast cancer.

However, pCR does not mean that every patient with pCR is guaranteed never to have recurrence, and lack of pCR does not automatically mean that treatment has failed.

The prognostic meaning of pathological response varies between cancer types.

Common chemotherapy regimens used before surgery

There is no single “neoadjuvant chemotherapy drug.”

The regimen is selected according to the cancer.

Cancer	Examples of systemic treatment approaches
Breast cancer	Anthracycline/taxane-based chemotherapy; HER2-directed or immunotherapy-containing regimens when indicated
Rectal cancer	FOLFOX or CAPOX in selected strategies; fluoropyrimidine-based chemoradiation in appropriate cases
Oesophageal cancer	Platinum/fluoropyrimidine-based chemotherapy or carboplatin/paclitaxel-based chemoradiation depending on treatment strategy
Gastric cancer	Fluoropyrimidine/platinum-based or other perioperative regimens depending on tumour and guideline
Pancreatic cancer	Modified FOLFIRINOX or gemcitabine-based approaches in selected patients
NSCLC	Platinum-doublet chemotherapy, sometimes combined with immunotherapy
Bladder cancer	Cisplatin-based combination chemotherapy in eligible patients
Osteosarcoma	Multi-agent chemotherapy including methotrexate, doxorubicin and cisplatin in established protocols

These are examples, not prescriptions. A regimen appropriate for one patient may be inappropriate for another.

Side effects of neoadjuvant chemotherapy

Side effects vary according to the drugs used, doses, treatment duration and the patient’s health.

Common effects can include fatigue, nausea or vomiting, reduced appetite, hair loss, mouth sores, changes in taste, diarrhoea or constipation, low white blood cell counts, anaemia, low platelet counts, increased infection risk, peripheral neuropathy, and skin or nail changes.

Some chemotherapy drugs can cause specific organ-related effects.

For example, platinum drugs can affect kidney function, hearing or nerves, while anthracyclines can have cardiac toxicity.

The oncology team therefore monitors patients throughout treatment.

Can side effects be managed?

Yes. Modern oncology includes extensive supportive care.

Depending on the treatment, supportive measures may include anti-nausea medicines, hydration, growth-factor support when indicated, nutritional support, pain management, management of diarrhoea or constipation, treatment of infections, blood transfusion when medically required, dose modification and temporary treatment delays.

Patients should report significant symptoms early rather than waiting for the next appointment.

Warning signs during chemotherapy

A patient receiving chemotherapy should have clear instructions from the treating cancer centre about when to seek urgent medical attention.

Depending on the treatment, potentially serious symptoms can include fever, chills, difficulty breathing, severe weakness, persistent vomiting, severe diarrhoea, bleeding, confusion, severe dehydration, and new or rapidly worsening pain.

Fever during chemotherapy can represent a medical emergency.

If fever, shaking chills, uncontrolled vomiting, chest pain, breathlessness, collapse or rapidly worsening infection develops, seek a local emergency department immediately. Do not wait for the next scheduled chemotherapy appointment or use WhatsApp as emergency care.

Neoadjuvant chemotherapy and surgery

One of the major objectives of neoadjuvant treatment is to reach surgery at an appropriate time.

Before surgery, the team considers tumour response, resectability, general health, blood counts, organ function, nutritional status, infection risk, timing of the last chemotherapy cycle, and whether additional treatment is required.

The surgical procedure may be less extensive in some patients if the tumour responds well, although this cannot be guaranteed.

Does neoadjuvant chemotherapy make surgery safer?

Not necessarily in every patient.

The purpose may be to improve tumour resectability or make the operation more effective, but chemotherapy itself can cause anaemia, low blood counts, nutritional problems or other toxicities that need to be corrected before surgery.

The surgical and oncology teams therefore coordinate the timing carefully.

Neoadjuvant chemotherapy versus chemoradiotherapy

These terms are sometimes confused.

Neoadjuvant chemotherapy means systemic chemotherapy before definitive local treatment.

Neoadjuvant chemoradiotherapy combines chemotherapy with radiation before surgery.

The choice depends on the cancer.

For example, preoperative chemoradiation has an established role in selected rectal and oesophageal cancers, whereas chemotherapy alone may be appropriate in other disease settings. See external beam radiotherapy in India. Selected cases may also be discussed against proton beam therapy in India.

Neoadjuvant chemotherapy versus total neoadjuvant therapy

Total neoadjuvant therapy (TNT) means that the major components of systemic chemotherapy and radiation intended as preoperative treatment are delivered before surgery.

TNT has become particularly important in the management of selected locally advanced rectal cancers.

The sequence can vary. Chemotherapy then chemoradiation then surgery, or chemoradiation then chemotherapy then surgery, may be used depending on the patient’s disease and treatment protocol.

NCI currently describes TNT as a preferred approach for many patients with locally advanced rectal cancer without distant metastases, while acknowledging that treatment selection remains disease-specific.

Neoadjuvant chemotherapy success rate

There is no single success rate for neoadjuvant chemotherapy.

Response depends on the cancer type, stage, molecular subtype, chemotherapy regimen and individual patient.

Doctors may use several different measures of response: tumour shrinkage on imaging, radiological response, clinical response, pathological complete response, major pathological response, ability to proceed to surgery, R0 resection, disease-free survival, event-free survival and overall survival.

For example, studies of neoadjuvant treatment in NSCLC have reported meaningful differences in pathological response and event-free survival for selected chemo-immunotherapy approaches, but these results should not be generalised to other cancers.

Can neoadjuvant chemotherapy cure cancer?

In selected cancers, neoadjuvant treatment can be part of a curative-intent treatment plan.

However, chemotherapy before surgery does not independently guarantee cure.

The overall outcome depends on cancer type, stage, tumour biology, response to treatment, completeness of surgery, lymph-node involvement, presence or absence of metastases, postoperative treatment and long-term disease behaviour.

The word “neoadjuvant” describes when treatment is given; it does not by itself indicate whether treatment is curative or palliative.

Cost of neoadjuvant chemotherapy in India

The cost of neoadjuvant chemotherapy in India varies substantially because there is no single neoadjuvant chemotherapy protocol.

GAF Healthcare partner planning for the named neoadjuvant chemotherapy pathway is $2,500–$10,000, typically Cycles before surgery · 2–4 months. Neighbouring United States comparison figures are $15,000–$45,000.

This should be treated as an indicative planning range rather than a guaranteed package price.

The total bill can depend on cancer type, stage, chemotherapy protocol, number of cycles, generic versus branded medicines, targeted therapy, immunotherapy, hospital category, city, day-care versus inpatient treatment, blood tests, imaging, port placement, specialist consultation, supportive medicines, management of complications, surgery after chemotherapy, and radiation therapy if required.

Therefore, patients should request a written treatment estimate based on their actual pathology and proposed regimen.

Estimated cost components

Cost component	Usually included?
Medical oncology consultation	May be separate
Blood tests	May be separate
Imaging	Usually separate
Chemotherapy drugs	Depends on package
Day-care infusion	Depends on hospital
Nursing charges	Depends on hospital
Anti-nausea medicines	May be included or separate
Growth-factor injections	Usually additional
Port/PICC placement	Usually additional
Hospital admission	Additional if required
Surgery	Separate
Radiation therapy	Separate
Targeted therapy	Often substantially increases cost
Immunotherapy	Often substantially increases cost

Surgery is usually estimated separately. Neighbouring adjuvant chemotherapy is $2,500–$10,000 if postoperative cycles are later required.

Neoadjuvant chemotherapy cost for international patients

For international patients, the treatment budget should include more than the chemotherapy bill.

Additional expenses may include initial specialist consultation, pathology review, imaging, molecular testing, chemotherapy, supportive medication, surgery, hospital stay, accommodation, local transportation, food, attendant expenses, medical visa-related expenses, follow-up visits and emergency care if required.

The duration of stay can also vary because some patients may need to remain in India through several cycles, while others may return home between treatment phases if their oncology team considers that medically appropriate.

A medical travel plan should be based on the actual treatment schedule, not simply the number of chemotherapy cycles.

Neoadjuvant chemotherapy cost by Indian city

There is no reliable single national tariff. GAF Healthcare uses one national partner planning band of $2,500–$10,000 rather than inventing city-specific prices.

International patients comparing medical oncologists listing Neoadjuvant Chemotherapy commonly start with Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad. Partner medical oncology hospitals in Delhi NCR, Mumbai and Bengaluru, and in Chennai and Hyderabad, are a typical first filter. City sheets include Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad. Pune, Kolkata, Ahmedabad, Kochi, Jaipur, Chandigarh, Lucknow and Indore are not live GAF catalog cities on this site.

City	Catalogue doctors list	India planning band
Delhi NCR	Medical oncologists listing Neoadjuvant Chemotherapy	$2,500–$10,000
Mumbai	Medical oncologists listing Neoadjuvant Chemotherapy	$2,500–$10,000
Bengaluru	Medical oncologists listing Neoadjuvant Chemotherapy	$2,500–$10,000
Chennai	Medical oncologists listing Neoadjuvant Chemotherapy	$2,500–$10,000
Hyderabad	Medical oncologists listing Neoadjuvant Chemotherapy	$2,500–$10,000

How to choose a centre

Instead of choosing a centre based only on advertising or a generic treatment page, patients should consider whether the campus has the appropriate expertise for their specific cancer.

Important questions include whether the centre has a dedicated medical oncology department, whether multidisciplinary tumour-board review is available, whether the hospital has the required surgical specialty, whether advanced pathology is available, whether molecular and biomarker tests are accessible, whether radiation oncology is available when required, whether chemotherapy can be administered safely in a day-care setting, whether emergency medical support is available, whether the centre manages complications, whether the hospital can coordinate surgery after neoadjuvant treatment, and whether it has experience with international patients if required.

Hospital selection should therefore be cancer-specific rather than based solely on hospital reputation.

Why consider India?

India has a large network of cancer centres providing medical oncology, surgical oncology, radiation oncology, pathology, imaging and multidisciplinary cancer services.

GAF Healthcare coordinates named partner programmes in Delhi NCR, Mumbai, Bengaluru, Chennai and Hyderabad. The appropriate centre depends on the cancer type and treatment complexity rather than city alone.

For complex cancers such as pancreatic cancer, sarcoma, oesophageal cancer or locally advanced rectal cancer, access to the appropriate multidisciplinary team can be particularly important.

What should international patients send before travelling?

Patients seeking an opinion for neoadjuvant chemotherapy should ideally provide:

1. Biopsy report
2. Histopathology report
3. Immunohistochemistry report
4. Molecular or biomarker reports, if available
5. CT/MRI/PET-CT reports
6. Imaging CDs or digital images where available
7. Previous treatment records
8. Blood-test reports
9. Discharge summaries
10. Current medication list
11. Relevant medical history
12. Previous chemotherapy details, if treatment has already started

A complete medical record allows the oncology team to assess the diagnosis and determine whether additional testing is needed.

How GAF Healthcare can help international patients

For international patients considering cancer treatment in India, the process can be coordinated around the patient’s existing medical records.

The typical pathway can include medical records, oncology review, a treatment plan, a hospital estimate, travel planning, treatment coordination and follow-up.

The final medical decision remains with the treating oncology team.

A treatment coordinator can help organise records, obtain hospital opinions, coordinate appointments and assist with practical arrangements for travel and treatment.

Questions to ask your oncologist before starting treatment

About the diagnosis

• What is my exact cancer type?
• What is the current stage?
• Is the tumour resectable?
• Are lymph nodes involved?
• Is there evidence of distant spread?

About treatment

• Why are you recommending chemotherapy before surgery?
• What is the goal of the treatment?
• Which drugs will I receive?
• How many cycles are planned?
• How frequently will treatment be given?
• Will I need immunotherapy or targeted therapy?
• Will radiation be part of the treatment?

About surgery

• When will surgery be reconsidered?
• What operation is currently planned?
• Could the operation change depending on response?
• What happens if the tumour progresses?

About side effects

• Which side effects are most likely?
• Which symptoms require emergency attention?
• Will I need a port?
• How will my blood counts and organ function be monitored?

About cost

• What is included in the chemotherapy estimate?
• Are supportive medicines included?
• Are scans included?
• Are molecular tests included?
• What happens financially if additional cycles are needed?

Advantages and limitations of neoadjuvant chemotherapy

Potential advantages

• Can shrink selected tumours before surgery
• Treats systemic microscopic disease earlier
• May improve resectability in selected cancers
• May allow less extensive surgery in some situations
• Provides an opportunity to assess treatment response before surgery
• Can identify cancers that progress despite treatment before a major operation

Potential limitations

• Treatment can cause significant side effects
• Surgery may need to be delayed
• Not every tumour responds
• Some tumours can progress during treatment
• Treatment can affect nutritional status and blood counts
• Some patients cannot tolerate particular chemotherapy regimens
• The optimal sequence differs between cancer types

These benefits and limitations need to be considered for the individual cancer rather than applied universally.

Frequently asked questions

What is neoadjuvant chemotherapy?

Neoadjuvant chemotherapy is chemotherapy given before the main definitive treatment, usually surgery. It may be used to shrink the tumour, treat microscopic disease early, improve resectability or assess treatment response.

Is neoadjuvant chemotherapy the same as chemotherapy?

The drugs may be similar to drugs used in other settings, but “neoadjuvant” refers to when chemotherapy is given—before definitive local treatment.

Is neoadjuvant chemotherapy given before every cancer surgery?

No. It is used only for selected cancers and clinical situations. Some patients are better treated with surgery first.

How many chemotherapy cycles are required before surgery?

There is no standard number for all cancers. The number depends on the cancer type, stage, regimen and treatment strategy.

Can neoadjuvant chemotherapy shrink a tumour?

Yes, chemotherapy can shrink some tumours. However, the amount of response varies significantly between patients and cancer types.

Does everyone respond to neoadjuvant chemotherapy?

No. Some tumours respond strongly, some remain stable, and some progress.

Can surgery be avoided after neoadjuvant chemotherapy?

In selected cancers and clinical circumstances, non-operative management may be considered, but this is not the usual implication of neoadjuvant chemotherapy and depends heavily on cancer type and treatment response.

Is neoadjuvant chemotherapy painful?

The chemotherapy infusion itself is not usually painful, although inserting an IV line or port can cause temporary discomfort. Side effects may develop during or after treatment.

Does chemotherapy always cause hair loss?

No. Hair loss depends on the specific drugs and doses used.

Can patients work during neoadjuvant chemotherapy?

Some patients can continue working, while others need reduced activity because of fatigue, treatment schedules or side effects.

Can I travel to India for neoadjuvant chemotherapy?

International patients can seek cancer treatment in India, but treatment should be planned after review of the medical records and confirmation from the treating hospital.

What is the cost of neoadjuvant chemotherapy in India?

A preliminary GAF planning range is approximately $2,500–$10,000, typically Cycles before surgery · 2–4 months, but actual costs vary significantly according to cancer type, regimen, number of cycles, hospital, drugs and additional treatments.

Does the cost include surgery?

Usually not. Chemotherapy, surgery, radiation, imaging and hospitalisation are generally estimated separately unless a hospital provides a specific bundled treatment package.

Can neoadjuvant chemotherapy be combined with immunotherapy?

Yes, in selected cancers. Modern treatment for some resectable cancers, including selected NSCLC and breast cancers, can combine systemic chemotherapy with immunotherapy or targeted therapy when clinically appropriate.

What happens if the tumour grows during chemotherapy?

The oncology team will reassess the patient and may change the treatment strategy. Depending on the cancer, options can include another systemic regimen, radiation, surgery or another disease-specific approach.

Is neoadjuvant chemotherapy curative?

It can form part of a curative-intent treatment plan for selected cancers, but the treatment itself does not guarantee cure.

Key takeaways

• Neoadjuvant chemotherapy is not simply chemotherapy before an operation. It is a carefully planned component of multimodal cancer treatment.
• GAF Healthcare partner planning for this pathway is $2,500–$10,000, typically Cycles before surgery · 2–4 months.
• Neighbouring United States comparison figures are $15,000–$45,000.
• Neighbouring adjuvant planning is $2,500–$10,000 for cycles after surgery.
• Its role differs considerably between breast, rectal, oesophageal, gastric, pancreatic, lung, bladder, bone and other cancers.
• The most important factors are the exact cancer diagnosis, stage, tumour biology, resectability and overall health of the patient.
• Fever during chemotherapy belongs in a local emergency department, not on WhatsApp.
• For international patients, obtaining a specialist opinion before travelling can help clarify the expected treatment sequence, number of cycles, surgery timing, likely duration in India and estimated cost.

Related cancer treatment guides

Live GAF lists that often sit next to this page:

• Adjuvant Chemotherapy in India
• Breast Cancer Treatment in India
• Colon Cancer Treatment in India
• Pancreatic Cancer Treatment in India
• Ovarian Cancer Treatment in India
• Cervical Cancer Treatment in India
• External Beam Radiotherapy in India
• Chemotherapy cost sheet
• Immunotherapy cost sheet
• Targeted Therapy cost sheet
• Rectal Cancer Surgery cost sheet

Medical disclaimer

This page is intended for general educational and medical-travel information. It does not diagnose cancer or recommend a particular chemotherapy regimen, hospital, drug or surgery for an individual patient.

Cancer treatment decisions should be made by a qualified medical oncology and multidisciplinary cancer team after reviewing the patient’s pathology, imaging, stage, biomarkers, medical history and treatment goals.

Treatment protocols and drug availability can change as clinical evidence and regulatory approvals evolve.

Cost figures are indicative and may change according to hospital, city, cancer diagnosis, chemotherapy drug, dose, number of cycles, investigations, specialist fees, admission requirements and other clinical factors.

Last reviewed: October 2026

Sources and references

1. National Cancer Institute (NCI) — Neoadjuvant therapy definition and use before definitive treatment
2. National Cancer Institute — Rectal Cancer Treatment PDQ, including chemoradiation and total neoadjuvant therapy
3. National Cancer Institute — Breast cancer chemotherapy before surgery
4. National Cancer Institute — Non-Small Cell Lung Cancer Treatment PDQ, including neoadjuvant chemo-immunotherapy
5. National Cancer Institute — Pancreatic Cancer Treatment PDQ
6. National Cancer Institute — Bladder Cancer Treatment PDQ and cisplatin-based neoadjuvant evidence
7. National Cancer Institute — Osteosarcoma Treatment PDQ
8. National Cancer Institute — Gastric and oesophageal cancer treatment guidance, including the CROSS trial
9. American Society of Clinical Oncology (ASCO) — Evidence-based oncology practice guidelines
10. GAF Healthcare cost sheet — Neoadjuvant Chemotherapy ($2,500–$10,000; Cycles before surgery · 2–4 months)
11. GAF Healthcare cost sheet — Adjuvant Chemotherapy ($2,500–$10,000; cycles after surgery · 3–6 months)
12. GAF Healthcare cost sheet — Chemotherapy ($1,500–$8,000+)

Medical information should be interpreted in the context of current clinical guidelines and the individual patient’s diagnosis. Published hospital and provider cost estimates are indicative and can change without notice.